The long-term clinical outcomes of latanoprostene bunod 0.024% in glaucoma treatment at a tertiary glaucoma center

PurposeTo evaluate the clinical outcomes of latanoprostene bunod 0.024% (LB) in intraocular pressure (IOP) control in patients with glaucoma.MethodsThis retrospective cohort study analyzed eyes treated with LB between 01/2018 and 01/2020. Demographic and clinical data were collected at baseline and up to 24-months (mo). Primary outcomes were mean change in IOP ( increment IOP) from baseline in eyes switched from a prostaglandin analogue (PGA) to LB (Group 1) vs. eyes in which LB was added as a first PGA to a glaucoma regimen (Group 2).Results262 eyes of 162 patients were included. Overall, baseline IOP was 18.67 +/- 5.65 mmHg. Group 1 (n = 168 [64%]) and Group 2 (n = 66 [25%]) each individually had significant increment IOP at 1, 3, 6, 12, and 18 mo compared to baseline (p = 0.005). increment IOP and duration of IOP control (9.5 +/- 11.4 vs. 9.7 +/- 9.9 months) on LB was similar between Group 1 and 2 at all time points. Additional pharmacologic or surgical intervention was required in 71 (27%) and 66 (25%) eyes, respectively, and LB was stopped in 24 (9.1%) eyes due to side effects.DiscussionLB successfully reduced IOP and was well-tolerated in our cohort. PGA naivete does not seem to influence the LB efficacy or its duration of effect.